Product Description
Retatrutide is an investigational triple-receptor hormone agonist (targeting GLP-1, GIP, and glucagon receptors) developed by
Eli Lilly. A 40mg vial or pen found online is an unapproved, unregulated research peptide or illicit product, as the medication is still undergoing Phase 3 clinical trials and lacks official therapeutic approval
Retatrutide is an investigational triple-receptor hormone agonist (targeting GLP-1, GIP, and glucagon receptors) developed by
Eli Lilly. A 40mg vial or pen found online is an unapproved, unregulated research peptide or illicit product, as the medication is still undergoing Phase 3 clinical trials and lacks official therapeutic approval
Retatrutide is an investigational triple-receptor hormone agonist (targeting GLP-1, GIP, and glucagon receptors) developed by Eli Lilly. A 40mg vial or pen found online is an unapproved, unregulated research peptide or illicit product, as the medication is still undergoing Phase 3 clinical trials and lacks official therapeutic approvalRetatrutide is an investigational triple-receptor hormone agonist (targeting GLP-1, GIP, and glucagon receptors) developed by Eli Lilly. A 40mg vial or pen found online is an unapproved, unregulated research peptide or illicit product, as the medication is still undergoing Phase 3 clinical trials and lacks official therapeutic approval